{"nctId":"NCT01141283","briefTitle":"Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase","startDateStruct":{"date":"2003-04"},"conditions":["Osteoarthritis"],"count":290,"armGroups":[{"label":"BTDS","type":"EXPERIMENTAL","interventionNames":["Drug: Buprenorphine transdermal patch"]}],"interventions":[{"name":"Buprenorphine transdermal patch","otherNames":[]},{"name":"Buprenorphine transdermal patch","otherNames":[]},{"name":"Buprenorphine transdermal patch","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with moderate to severe osteoarthritic (OA) pain who completed all visits of the double-blind phase on study drug, or who discontinued study drug due to lack of therapeutic effect in the double-blind phase, but still completed all visits of the double-blind phase off study drug, are eligible to enroll in the extension phase.\n\nExclusion Criteria:\n\n* Excluded from the study are subjects who ingest \\> 2500 mg/day acetaminophen as part of their current stable nonopioid analgesic regimen.\n* Subjects requiring long-acting opioid analgesics \\[once- or twice-daily dosing with an every (q) 24 hour (h) or q12h drug\\] or transdermal fentanyl during the extension phase should be discontinued from the study.\n\nRefer to core study for additional inclusion/exclusion information.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Participants With Adverse Events as a Measure of Safety and Tolerability","description":"Safety was assessed using reports of adverse events, clinical laboratory results, findings from physical examinations, and vital sign measurements.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"202","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":290},"commonTop":["Headache","Application site rash","Application site erythema","Nausea","Constipation"]}}}